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Processing of rat prodynorphin (proDyn) by the mouse prohormone convertase PC1 was investigated. Recombinant vaccinia virus vectors were 
used to coexpress proDyn and PC1 in rat PC12 pheochromocytoma and mouse AtT-20 corticotroph cells. In vitro experiments were also conducted 
by co-incubating purified proDyn and PCl. The results demonstrate that PC1 cleaves proDyn at pairs of basic residues to yield 10 and 16 kDa high 
molecular weight (HMW) intermediates. Additionally, PC1 cleaves proDyn at a single arginine residue to yield an 8 kDa product and the C-peptide. 
This demonstrates that PC1 cleaves proDyn at single and pairs of basic residues. 
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1. Introduction 
ProDyn is the precursor molecule of three leucine- 
enkephalin (Leu-Enk) extended opioid peptides known 
as dynorphin A,_i7 (Dyn Al_& dynorphin B,_is (Dyn 
B1_,J and a-neo-endorphin (a-NE) [l]. In the rat, pro- 
Dyn is expressed in the central nervous system (CNS) 
and periphery (i.e. striatum, hypothalamus, hippocam- 
pus, cerebral cortex, pituiatry, adrenal, gut and testis) [2] 
and is processed in a tissue specific manner to yield dif- 
ferent combinations of end products [3]. In the pituitary, 
proDyn derived products are localized in anterior lobe 
gonadotrophs [4], intermediate lobe melanotrophs [5] 
and neural lobe neurosecretory terminals [6]. Interest- 
ingly, gonadotrophs store high levels of partially proc- 
essed high molecular weight (HMW) intermediates and 
only low levels of final products such as Dyn A,_,, or 
Dyn Bi-rs 171. 
All neuropeptides are derived through enzymatic 
processing from biologically inactive precursor proteins. 
Processing of the pro-neuropeptides occurs at the car- 
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boxy- (C-) terminal of basic residues by the action of an 
endopeptidase, followed by the trimming action of car- 
boxypeptidase E (CPE) and sometimes by C-terminal 
amidation [8]. The most common processing site is the 
pair of basic amino acids ‘lysine-arginine’ (KR) [9]. 
Other paired basic cleavage sites are processed, such as 
‘KK’, ‘RR’ or ‘RK’, as well as single basic residues such 
as ‘R’. Six processing enzymes, generally referred to as 
the prohormone convertases (PCs) have been discovered 
in mammalian species. They are PC1 [lo] (also named 
PC3 [l l]), PC2 [10,12], furin [13] (also named PACE for 
Paired dibasic Amino acid-Cleaving Enzyme [14]), PC4 
[15,16], PACE4 [17] and PC5 [18] (also named PC6 [19]). 
ProDyn has 4 KR and 2 single R sites important for 
the formation of Dyn peptides (Fig. 1). Cleavage at a 
single R site between Dyn B,_,, and the C-peptide is 
necessary for the production of Dyn B,_,3, while cleavage 
at the single R site within the Dyn A,_,, peptide results 
in the formation of Dyn A,_,. Furthermore, three poten- 
tial cleavage sites (RR or RK) are found following the 
Leu-Enk sequences in the proDyn precursor. Cleavage 
at these sites could result in Leu-Enk being formed. Our 
previous studies looking at the processing of proDyn in 
the anterior pituitary had characterized HMW interme- 
diates in this tissue [7]. In the present study we examined 
the direct actions of PC1 on proDyn. Our data demon- 
A. Dupuy et al. IFEBS Letters 337 (1994) 6065 
strates that PC1 cleaves proDyn at both single and pairs 
of basic residues to produce HMW intermediates. 
2. Materials and methods 
2.1. Vaccinia virus (VV) 
The full-length proDyn cDNA clone, pFLRD3 [20], was the gener- 
ous gift of Dr. J. Douglass (Portland, Oregon). The EcoRI fragment 
containing the entire coding region of proDyn was blunt-ended and 
subclonedinto the W vector pMJ601 into the SmaI site. Full-length 
PC1 was subcloned into the W vector nVV3 as ureviouslv described 
[21]. PC12 and AtT-20 cells were infectedwith a mixture of VVproDyn 
and either VVWT (wild-type control) or VVPCl at various multiplic- 
ities of infection for 2 h. The medium (DMEM) was then replaced and 
the cells were harvested following a post-infection period of 16 h. 
2.2. Peptide analysis 
Cells were washed 2 times in fresh medium and extracted in acidified 
methanol (methano1:O.l N HCI; 1:l v/v) [I. After centrifugation at 
15,000 x g for 30 min at 4”C, the supernatants were collected and 
lyophilized. The samples were resuspended and submitted to reverse 
phase-high pressure liquid chromatography (RP-HPLC) or size exclu- 
sion chromatography. For RP-HPLC, the samples were resuspended 
in 0.1% trifluoroacetic acid (TFA) and separated using a 5 bum C,s 
column (3OOA), 25 x 0.46 cm (Chromatographic Sciences Co.) using a 
&60% acetonitrile gradient increasing at a rate of 0.5% /min. Gel 
chromatography is performed using Sephadex G-50 swollen in 0.1% 
formic acid. 0.1% BSA 171. Fractions were collected. dried. resusoended . . , , 
and submitted to RIA. Protein standards run under the same conditions 
were used to determine the elution times of the peptide of interest. 
2.3. In vitro studies 
Rat proDyn was overexpressed in dhfr- Chinese hamster ovary 
(CHO)&ls as previously described [22]. The protein was purified from 
200 ml of filtered 24 h conditioned Onti-MEM (Gibco) containing 100 
&ml aprotinin using RP-HPLC, firsi with a semi-preparative column 
eluted with TFA/acetonitrile, (Vydac C-4,250 x 10 mm), during which 
proDyn eluted at 52% acetonitrile, followed by an analytical column 
(Vydac C-4, 250x4.6 mm) eluted in 0.2% heptafluorobutyric acid/ 
acetonitrile during which proDyn eluted at 56% acetonitrile. Elution of 
proDyn was monitored by Western blotting of fractions using a mixture 
of antisera directed against he N- and C-termini of proDyn. Purity of 
the final product was confirmed by the presence of a symmetrical peak 
by absorbance at 215 nm; a single 30 kDa band upon Coomassie 
staining of a 15% polyacrylamide gel; and microsequencing, which 
revealed a single amino-terminus derived sequence of 20 amino acids 
corresponding exactly to those of rat proDyn (data not shown). The 
presence of an intact C-terminus was verified by Western blotting using 
C-terminally directed antiserum. The yield was about 500 pg. 87 kDa 
mPC1 was purified using fast protein liquid chromatography from 
conditioned medium obtained from overexpressing CHO cells as previ- 
ously described [23]. Various amounts (l-25 pg) of purified proDyn 
were incubated with 50 ng of purified PCl. The incubations were 
carried out in 100 mM sodium acetate, pH 5.5, containing 5 mM CaCl, 
and 0.1% Brij for 16 h at 37’C. The samples were then submitted to 
G-50 chromatography and the fractions analyzed by RIA. In the case 
of Dyn B,_,, and &-NE RIA analysis, an aliquot of each fraction was 
pretreated with carboxypeptidase B before RIA in order to remove the 
C-terminal basic amino acid residues and thus permit RIA detection. 
The C-peptide-ir fractions were collected and microsequenced on an 
Applied Biosystems equenator. 
2.4. BIAS 
The RIAs used in the present study for Dyn B,_,,, C-peptide and 
a-NE have been extensively characterized [7]. The Dyn B,_,, and a-NE 
P 
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antibodies are carboxy-terminus directed and under RIA conditions, 
neither antibody can recognize HMW intermediates containing a hin- 
dered antigenic site at the carboxy-terminus. The C-peptide antibody 
recognizes any pro-Dyn derived HMW intermediate with a C-peptide 
in its carboxy-terminus. 
3. Results 
We examined the processing capability of PC1 on the 
proDyn precursor by coinfecting PC12 and AtT-20 cells 
with VVproDyn and VVPCl. The cells were extracted 
and submitted to RP-HPLC (Fig. 2) or size exclusion 
chromatography (Fig. 3). The fractions obtained were 
analyzed for proDyn C-terminal peptide and Dyn B,_,, 
immunoreactivities (ir). In Fig. 2A, extracts of PC12 cells 
infected with VVproDyn demonstrated high expression 
levels of proDyn precursor and very little processed 
products, as detected with the C-peptide RIA. A purified 
proDyn precursor standard (see section 2) was injected 
in a separate chromatogram under the same conditions. 
ProDyn eluted at 50% acetonitrile at the identical posi- 
tion to the C-peptide-ir detected in VVproDyn PC12 
cells. In Fig. 2B, processed products were observed in 
PC12 cells co-infected with VVproDyn and VVPCl. 
C-peptide-ir eluted at 22% acetonitrile, corresponding to 
the elution of a synthetic C-peptide standard. C-peptide- 
ir was also observed eluting at 32% acetonitrile. This 
C-peptide-ir most likely corresponds to a HMW interme- 
diate described in Fig. 3. 
In Fig. 3, AtT-20 cells were infected with VVproDyn 
or coinfected with VVproDyn and VVPCl. The frac- 
tions obtained were analyzed with the C-peptide (Fig. 3 
A,B) and Dyn B1_13 (Fig. 3C,D) RIAs. Large amounts 
of proDyn precursor were observed eluting from the 
column at the void volume (I’,) as detected with the 
C-peptide RIA (Fig. 3A). Very small amounts of proc- 
essed products were observed at an M, of 10 kDa and 
at the position of the C-peptide. This may be due to the 
endogenous processing enzymes found in AtT-20 cells, 
which express PC1 and lower levels of PC2 and furin 
[24]. Co-infection of AtT-20 cells with VVproDyn and 
VVPCl resulted in large increases in the processed prod- 
ucts at an il4, of 10 kDa and at the position of the 
C-peptide (Fig. 3B). The same two sets of fractions were 
analyzed with the Dyn B,_,, RIA (Fig. 3C,D). Very little 
ir-Dyn B1_,3 was observed when AtT-20 cells were in- 
fected with VVproDyn only (Fig. 3C). The proDyn pre- 
cursor eluting at the void volume was poorly detected 
because of the strong requirement of the Dyn B,_,, anti- 
body for a free C-terminus. Therefore, most of the ir- 
Dyn B,_,, detected represents peptide products in which 
Fig. 1. Schematic representation of the proDyn precursor. 
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Fig. 2. RP-HPLC analysis of PC12 cells infected with (A) VVproDyn 
and (B) VV:proDyn and VVPCl. The fractions were collected, lyo- 
philized, resusupended and analyzed with the C-peptide RIA. The ar- 
rows indicate the elution positions of the standard peptides. The exper- 
iment was repeated 2 times. 
the C-peptide has been cleaved. Dyn B,_,,-ir was detected 
in AtT-20 cells that were coinfected with VVproDyn and 
W:PCl (Fig. 3D). The Dyn B,-,,-ir eluted at an M, of 
approximately 8 kDa. The sum of the data presented in 
_. 
B tvv:prc.cw . W:PCI, 25 
Fig. 3 indicates that PC1 cleaves proDyn into HMW 
intermediates of 8 and 10 kDa. The difference between 
these two peptide products resides in the absence or pres- 
ence of the C-peptide, as analyzed with the C-peptide 
RIA. We did not observe Dyn B,_,,-ir corresponding to 
the elution postion of Dyn AB or Dyn B,_r3, suggesting 
that PC1 does not further cleave the observed HMW 
intermediates. 
We also examined the processing of proDyn by PC1 
under in vitro conditions. Recombinant proDyn precur- 
sor was purified from the medium of overexpressing Chi- 
nese hamster ovary cells [22]. Recombinant PC1 was 
purified from a similar system [23]. Between 15 and 30 ,ug 
of proDyn were incubated with PCl. The samples were 
submitted to size exclusion chromatography and the 
fractions obtained were analyzed using the C-peptide 
(Fig. 4A), Dyn B,_,, (Fig. 4B) and &-NE (Fig. 4C) RIAs. 
The C-peptide RIA analysis (Fig. 4A) demonstrated that 
nearly 80% of the ir eluted at positions other than that 
of the intact proDyn precursor, indicating an almost 
complete cleavage by PC1 in vitro. The majority of the 
C-peptide-ir eluted at an M, of 10 kDa, similar to that 
observed in the VV infection experiments. Furthermore, 
the synthetic C-peptide-ir was also detected at the posi- 
tion where the C-peptide standard elutes. Analysis of 
these fractions with the Dyn B1_r3 RIA (Fig. 4B) demon- 
strated the formation of the 8 kDa intermediate, which 
was not detectable with the C-peptide RIA (Fig. 4A). 
Further analysis of these fractions with the a-NE RIA 
demonstrated the presence of a HMW intermediate at 
Fraction Number (2.2 ml I tube) 
Fig. 3. Size exclusion chromatography of extracts from AtT-20 cells infected with (AC) VVproDyn and (B,D) VVproDyn and VVPCl. The fractions 
were analyzed with the (A,B) C-peptide and (C,D) Dyn B,_,3 RIAs. The molecular weight markers are a-lactalbumin (14.2 kDa) and aprotinin (6.5 
kDa). The void volume (V,) is determined with Dextran blue and the total volume (I’,) is determined with cobalt chloride. Other standards are 
indicated by arrows include the C-peptide and Dyn AB. The experiment was repeated 2 times. 
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Fig. 4. Size exclusion chromatography of proDyn precusor incubated 
with PC1 under in vitro conditions. The fractions obtained were ana- 
lyzed with (A) C-peptide (B) Dyn B,_,, and (C) cc-NE RIAs. Prior to 
RIAs with Dyn B,_,3 and a-NE, aliquots of each fraction were treated 
with CPB to remove C-terminal basic amino acids, and thus permit 
access to antigenic determinants. No ir-Dyn B,_,g or ir-&-NE is ob- 
served prior to CPB treatment. The markers are identical to those 
described in Fig. 3. 
approximately 16 kDa (Fig. 4C). This intermediate was 
present at much lower levels in comparison to the inter- 
mediates observed in Fig. 4A and B. A summary of the 
data in Fig. 4 is presented in Table 1. 
In a separate experiment, we incubated 5 ,ug of pro- 
Dyn precursor and PC 1. The sample was submitted to 
RP-HPLC under the same conditions shown in Fig. 2. 
The fractions were analyzed with the C-peptide RIA. 
The fractions containing C-peptide-ir eluting at 22% ace- 
tonitrile (same as C-peptide standard) were collected and 
submitted to sequence analysis. Nine cycles were carried 
out to obtain the N-terminal sequence of this C-peptide- 
ir. The following sequence was obtained: X-X-E-N-P-N- 
T-Y-S. The first two residues (X), given the low signal 
and the initial high background could not be identified 
unequivocally. The subsequent 7 cycles were clearly 
identified. The full rat C-peptide sequence is: S-Q-E-N-P- 
N-T-Y-S-E-D-L-D-V. This data demonstrates cleavage 
by PC1 at the post-single R site as follows: V-V-T-R- 1 S- 
Q-E-N-P-N-T-Y-S-E-D-L-D-V. 
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4. Discussion 
The present study demonstrates the processing of pro- 
Dyn by PC1 in a cellular environment (PC12 and AtT-20 
cells) and under in vitro conditions. The two studies 
yielded similar results, namely that PC1 cleaves proDyn 
both at pairs of basic residues and at a single R cleavage 
site to yield HMW intermediates. 
We propose the following model for the cleavage of 26 
kDa proDyn by PC1 (Fig. 5). The major site of cleavage 
by PC1 is the KR site at the N-terminal of a-NE (site 1). 
PC1 efficiently cuts this site since 61% of all processed 
products obtained are found at the elution position of the 
10 kDa HMW intermediate (Table 1). The 2nd most 
important site of cleavage for PC1 is the single R residue 
(site 2). This cleavage results in the formation of the 8 
kDa HMW intermediate and the C-peptide. Under in 
vitro conditions, we observe almost equal quantities of 
the 8 kDa HMW intermediate and of the C-peptide (350 
and 400 pmol, respectively), which together represent 
33% of processed proDyn molecules. Finally, a minor 
cleavage C-terminal to the KR pairs of a-NE (site 3), 
results in the formation of the 16 kDa HMW intermedi- 
ate (Fig. 4C), and represents only 1% of the total proc- 
essed products. The ratios of processed HMW intermedi- 
ates obtained in these in vitro experiments are consistent 
with those observed in the cellular studies and to those 
obtained by examining the steady state levels of proDyn 
products in the anterior pituitary [7]. 
The proDyn HMW intermediates (8, 10 and 16 kDa) 
produced by PC1 are similar to the proDyn forms we 
previously described in the anterior pituitary [7]. This 
correlation is interesting for the following reasons. The 
anterior lobe expresses high levels of PC1 but much 
lower levels of PC2 or furin [24]. Our recent specific 
analysis of anterior lobe gonadotrophs, the cells which 
express proDyn, demonstrated high levels of PC1 and 
much lower levels of PC2 ([25]; and unpublished obser- 
vation). This suggests that in the anterior lobe gona- 
Table 1 
Ir levels of proDyn peptide products from in vitro experiments 
Product ir C-peptide ir Dyn B l-13 ir aNE 
(Pmol) (pmol) (pmol) 
PrDyn (un- 450 - 
processed) 
16 kDA - - 16 (1%) 
10 kDA 1400 (61%) - 
8kDA - 350 (15%) - 
C-Peptide 400 (18%) - - 
Other 100 (4%) 20 (1%) 2 (0.1%) 
In parentheses are shown the amounts of processed products as a 
percentage of total processed products. Total processed products are 
equal to the sum of all the values shown, except that of unprocessed 
proDyn (450 pmol). 
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Fig. 5. Proposed processing of proDyn by PCl. Preference of cleavage 
is in the following order: Site 1 > Site 2 > Site 3. 
dotrophs, the observed HMW proDyn intermediates are 
primarily derived from cleavage by PCl. The results of 
the present study support this notion since the proDyn 
precursor was processed to similar HMW intermediates 
by PCl. It should be noted that further processing to 
Dyn AB or Dyn B,_,, was not observed in the present 
study either in a cellular or in vitro environment. How- 
ever, the analysis of anterior lobe gonadotrophs demon- 
strated low levels of Dyn AB as well as Dyn B1_13 [7]. This 
suggests that further processing in anterior lobe gon- 
dotrophs is occurring; this may be due to the presence 
of other enzymes, such as the low levels of PC2 or furin. 
As an additional correlation, it is interesting to note that 
other proDyn expressing tissues such as the striatum 
[26], hypothalamus [7] or spinal cord [7], process the 
proDyn precursor much more completely than the ante- 
rior lobe. These tissues express higher levels of PC2 [27] 
than the anterior lobe gonadotrophs [24]. In preliminary 
experiments, we tested proDyn processing by PC2 using 
the W overexpression system and observed the forma- 
tion of Dyn B,_,, (data not shown). Taken together, our 
data indicate that PC1 cleaves proDyn to HMW inter- 
mediates and that further processing to final opioid pep- 
tide end products might require the actions of PC2 and/ 
or other enzymes. 
The processing of proDyn to HMW intermediates 
by PC1 is reminiscent of the actions of the PCs on an- 
other opioid peptide precursor, pro-opiomelanocortin 
(POMC) [21]. PC1 was shown to cleave POMC to/?-LPH 
and ACTH, but PC2 is required to obtain a-MSH and 
/?-endorphin. Once again, this suggests that PC1 is re- 
sponsible for the formation of larger intermediate mole- 
cules, while PC2 cleaves POMC to smaller peptide prod- 
ucts. Furthermore, our recent studies [28] examining the 
processing of proenkephalin indicate that PC1 is respon- 
sible for the formation of larger ‘enkephalin’ containing 
molecules, including Peptide B, but PC2 enhances the 
production of free enkephalins. Thus, an interesting as- 
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sociation can be made in cells which express the same 
precursor but differential evels of PC1 and PC2. Tissue- 
specific processing would therefore be highly dependent 
on the expression levels of each enzyme, and the resulting 
biological activity of the processed precursor could be 
modified. 
One of the unique features of the present study is the 
processing of proDyn by PC1 at a single R cleavage site. 
This is the first such demonstration with an endogenous 
substrate. Our data supporting cleavage at the single R 
residue, include the observation of the formation of the 
C-peptide in cellular experiments (Figs. 2 and 3) and 
under in vitro conditions (Fig. 4). Furthermore the 
N-terminal sequence of the observed C-peptide-ir une- 
quivocally proves cleavage at this site. At the present 
time, no recognition motif has been described for PC1 
(or PC2), as has been demonstrated for furin [29]. How- 
ever, a recent study [30] has proposed rules and tenden- 
cies for the cleavage at single basic residues. These crite- 
ria are met for the single R cleavage site in proDyn. The 
fact that PC1 cleaves this single R according to these 
rules and tendencies, suggests that the family of kexin/ 
subtilisin-like proteases may be responsible or partly re- 
sponsible for cleavage at single basic residues. Indeed, we 
have observed that PC2 and furin can produce, although 
less efficiently than PC1 , the C-peptide product, indicat- 
ing their capacity to cleave at the same single R residue. 
The actions of two other members, PC5 and PACE4, are 
untested. We cannot exclude that other processing en- 
zymes, not part of the kexin/subtilisin-like proteases, are 
also responsible for cleavage at single basic residues, as 
has been suggested previously [31]. 
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